Crystec are delighted to have been awarded the CPhI Excellence in Pharma Award for Contract Services and Outsourcing. The award was presented for Crystec’s modified supercritical anti-solvent (mSAS) technology for accelerated product development, and chosen from shortlisted companies including 3M, Alcami, Catalent Pharma Services and Merck.
China Resources Pharmaceutical Group and CrystecPharma enter agreement to bridge research and innovation between China and the UK
Crystec’s Chief Scientist, Prof. Peter York, and China Resources Pharmaceutical’s President, Mr. Wang Chuncheng, were hosted by the UK Department of International Trade to sign a strategic cooperation agreement.
The partnership between Crystec and Juniper Pharma Services has reached another key milestone, with Crystec’s commercial scale supercritical fluid rig now on-site at Juniper Pharma Services in Nottingham.
Crystec are delighted to have been shortlisted for the RSC Emerging Technologies Competition, which is focused on accelerating the commercialisation of innovative technologies. Crystec will pitch their novel treatment for urge incontinence to a panel of experts at Chemistry Means Business in Manchester 13th - 14th June 2017.